177 related articles for article (PubMed ID: 24923897)
1. Thymoma with loss of keratin expression (and giant cells): a potential diagnostic pitfall.
Adam P; Hakroush S; Hofmann I; Reidenbach S; Marx A; Ströbel P
Virchows Arch; 2014 Sep; 465(3):313-20. PubMed ID: 24923897
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical differentiation between type B3 thymomas and thymic squamous cell carcinomas.
Su XY; Wang WY; Li JN; Liao DY; Wu WL; Li GD
Int J Clin Exp Pathol; 2015; 8(5):5354-62. PubMed ID: 26191237
[TBL] [Abstract][Full Text] [Related]
3. Cytokeratins in normal thymus and thymic epithelial tumors.
Fukai I; Masaoka A; Hashimoto T; Yamakawa Y; Mizuno T; Tanamura O
Cancer; 1993 Jan; 71(1):99-105. PubMed ID: 7677978
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms.
Kojika M; Ishii G; Yoshida J; Nishimura M; Hishida T; Ota SJ; Murata Y; Nagai K; Ochiai A
Mod Pathol; 2009 Oct; 22(10):1341-50. PubMed ID: 19648882
[TBL] [Abstract][Full Text] [Related]
5. Expression patterns for Bcl-2, EMA, β-catenin, E-cadherin, PAX8, and MIB1 in thymomas.
Suster D; Miller JA; Pihan G; Mackinnon AC; Suster S
Mod Pathol; 2021 Oct; 34(10):1831-1838. PubMed ID: 34135467
[TBL] [Abstract][Full Text] [Related]
6. Vascular architecture as a diagnostic marker for differentiation of World Health Organization thymoma subtypes and thymic carcinoma.
Pfister F; Hussain H; Belharazem D; Busch S; Simon-Keller K; Becker D; Pfister E; Rieker R; Ströbel P; Marx A
Histopathology; 2017 Apr; 70(5):693-703. PubMed ID: 27791295
[TBL] [Abstract][Full Text] [Related]
7. Expression of neurotrophin receptors in surgically resected thymic epithelial tumors.
Kim DJ; Yang WI; Kim SH; Park IK; Chung KY
Eur J Cardiothorac Surg; 2005 Oct; 28(4):611-6. PubMed ID: 16125946
[TBL] [Abstract][Full Text] [Related]
8. The use of antikeratin antiserum as a diagnostic tool: thymoma versus lymphoma.
Battifora H; Sun TT; Bahu RM; Rao S
Hum Pathol; 1980 Nov; 11(6):635-41. PubMed ID: 6161075
[TBL] [Abstract][Full Text] [Related]
9. Expression of proteasome subunit β5t in thymic epithelial tumors.
Yamada Y; Tomaru U; Ishizu A; Kiuchi T; Marukawa K; Matsuno Y; Kasahara M
Am J Surg Pathol; 2011 Sep; 35(9):1296-304. PubMed ID: 21836487
[TBL] [Abstract][Full Text] [Related]
10. Corpuscular thymoma: entity or variant of organotypical thymomas WHO B2/B3?
Laeng RH; Eimoto T; Kuo TT; Zettl A; Marx A; Moschopulos M; Tateyama H; Shimokawa K
Pathol Res Pract; 2006; 202(10):697-704. PubMed ID: 16887284
[TBL] [Abstract][Full Text] [Related]
11. [Thymomas and thymic carcinomas].
De Montpréville VT
Rev Mal Respir; 2010 Dec; 27(10):1281-7. PubMed ID: 21163404
[No Abstract] [Full Text] [Related]
12. Thymoma with pseudosarcomatous stroma: report of an unusual histologic variant of thymic epithelial neoplasm that may simulate carcinosarcoma.
Suster S; Moran CA; Chan JK
Am J Surg Pathol; 1997 Nov; 21(11):1316-23. PubMed ID: 9351569
[TBL] [Abstract][Full Text] [Related]
13. Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis.
Weissferdt A; Moran CA
Am J Surg Pathol; 2011 Sep; 35(9):1305-10. PubMed ID: 21836478
[TBL] [Abstract][Full Text] [Related]
14. [Morphometrical and immunohistochemical analysis of cortical and medullary thymoma: its correlation with invasiveness and association with myasthenia gravis].
Nomori H; Ishihara T; Torikata C
Nihon Kyobu Geka Gakkai Zasshi; 1990 Jan; 38(1):93-100. PubMed ID: 1691772
[TBL] [Abstract][Full Text] [Related]
15. Thymic carcinoma arising in thymoma is associated with alterations in immunohistochemical profile.
Kuo TT; Chan JK
Am J Surg Pathol; 1998 Dec; 22(12):1474-81. PubMed ID: 9850173
[TBL] [Abstract][Full Text] [Related]
16. Expression of c-Jun, p73, Casp9, and N-ras in thymic epithelial tumors: relationship with the current WHO classification systems.
Ma Y; Li Q; Cui W; Miao N; Liu X; Zhang W; Zhang C; Wang J
Diagn Pathol; 2012 Sep; 7():120. PubMed ID: 22974165
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic significance of cell kinetic parameters in World Health Organization type A and B3 thymomas and thymic carcinomas.
Roden AC; Yi ES; Jenkins SM; Donovan JL; Cassivi SD; Garces YI; Marks RS; Aubry MC
Hum Pathol; 2015 Jan; 46(1):17-25. PubMed ID: 25455993
[TBL] [Abstract][Full Text] [Related]
18. NOTCH1 intracellular domain immunohistochemistry as a diagnostic tool to distinguish T-lymphoblastic lymphoma from thymoma.
Jegalian AG; Bodo J; Hsi ED
Am J Surg Pathol; 2015 Apr; 39(4):565-72. PubMed ID: 25517959
[TBL] [Abstract][Full Text] [Related]
19. The MIC2 antibody 013. Practical application for the study of thymic epithelial tumors.
Chan JK; Tsang WY; Seneviratne S; Pau MY
Am J Surg Pathol; 1995 Oct; 19(10):1115-23. PubMed ID: 7573670
[TBL] [Abstract][Full Text] [Related]
20. [Immunohistochemical study of 11 epithelial tumors of the thymus or thymomas with anti-keratin antibodies: KL-1].
Caillaud JM; Carlu C; Bretel JJ; Arriagada R
Rev Mal Respir; 1988; 5(2):153-7. PubMed ID: 2455924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
